Table 4. HPV 6, 11, 16, 18- attributable fraction of total lifetime costs per diagnosis.
| Conditions | Total lifetime direct costs per disease (mill Euro) | HPV 16,18 fraction | HPV 6,11 fraction | HPV 6,11,16,18 fraction | Lower bound | Upper bound | HPV 6,11,16,18 attributable costs (mill Euro) | Lower bound | Upper bound | References | |
| a | b | C | d | a × b | a × c | a × d | |||||
| e | Cervical cancer | € 73.5 | 72.1% | 0.0% | 72.1% | 64.9% | 84.0% | € 53.0 | € 47.7 | € 61.8 | [26] |
| f | Repeated Pap smears | € 6.9 | 80.0% | 11.5% | 91.5% | - | - | € 6.3 | € 6.3 | € 6.3 | [15] |
| g | Management of abnormal Pap smears | € 32.1 | 85.0% | 9.0% | 94.0% | - | - | € 30.1 | € 30.1 | € 30.1 | [15] |
| h | Diagnosis of cervical dysplasia | € 14.9 | - | - | 35.0% | - | - | € 5.2 | € 5.2 | € 5.2 | [28] |
| i | CIN 1 treatment | € 6.3 | 27.6% | 10.5% | 38.1% | 32.2% | 45.3% | € 2.4 | € 2.0 | € 2.9 | [26] |
| l | CIN2 treatment | € 5.2 | 55.7% | 1.5% | 57.2% | 46.7% | 71.4% | € 3.0 | € 2.4 | € 3.7 | [26] |
| m | CIN3 treatment | € 8.0 | 55.7% | 1.5% | 57.2% | 46.7% | 71.4% | € 4.6 | € 3.7 | € 5.7 | [26] |
| n | Total cervical lesions (h + i + l + m) | € 15.2 | € 13.4 | € 17.5 | |||||||
| o | Total cervical dysplasia (f + g + n) | € 51.6 | € 49.9 | € 53.9 | |||||||
| p | Total cervical conditions (e + o) | € 146.9 | € 104.6 | € 97.6 | € 115.7 | ||||||
| q | Anal cancer | € 10.4 | - | - | 64.3% | 35.1% | 87.7% | € 6.7 | € 3.7 | € 9.2 | [26] |
| r | Head and neck cancer | € 224.0 | - | - | 26.4% | 24.7% | 27.2% | € 59.1 | € 55.3 | € 60.9 | [26] |
| s | Vulvar cancer | € 15.1 | - | - | 41.1% | 28.1% | 55.0% | € 6.2 | € 4.2 | € 8.3 | [26] |
| t | Vaginal cancer | € 4.0 | 57.6% | 9.30% | 66.9% | - | - | € 2.7 | € 2.7 | € 2.7 | [26] |
| u | Penile cancer | € 3.8 | 50.0% | - | 51.9% | 37.6% | 66.0% | € 2.0 | € 1.4 | € 2.5 | [26] |
| v | Anogenital warts (women) | € 41.3 | - | 90.0% | 90.0% | - | - | € 37.1 | € 37.1 | € 37.1 | [19] |
| z | Anogenital warts (men) | € 37.6 | - | 90.0% | 90.0% | - | - | € 33.8 | € 33.8 | € 33.8 | [19] |
| y | RRP ‡ | € 45.5 | - | 85.0% | 85.0% | 85.0% | 100.0% | € 38.6 | € 38.6 | € 45.5 | [7], [8] |
| w | Total non-cervical conditions (q + r + s + t + u + v + z + y) | € 381.7 | € 186.3 | € 176.9 | € 200.0 | ||||||
| w | Total burden (p + w) | € 528.6 | € 291.0 | € 274.5 | € 315.7 |
‡
Respiratory recurrent papillomatosis (RRP).
Italian data not available. The mean prevalence rates reported by the reference were informed by the outcomes of an ongoing metanalysis on global data compiled by he Unit of Infections and Cancer at the Istitut Catala d'Oncologia. No confidence intervals for the reported mean values were given.